Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. (Q50583511)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 September 2009

Language	Label	Description	Also known as
English	Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.	scientific article published on 8 September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Pseudomonas aeruginosa

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Eric T Weimer

1

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Sean E Ervin

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Daniel J Wozniak

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Steven B Mizel

4

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

language of work or name

0 references

publication date

8 September 2009

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

27

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

48

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

6762-6769

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Early infection and progression of cystic fibrosis lung disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Mucosal adjuvant activity of flagellin in aged mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Role of Toll-like receptors in costimulating cytotoxic T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Mucosal administration of flagellin induces innate immunity in the mouse lung

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Two genetic loci produce distinct carbohydrate-rich structural components of the Pseudomonas aeruginosa biofilm matrix

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Gene replacement in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

The measurement of relative antibody affinity by ELISA using thiocyanate elution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Characterization of chronic bronchopulmonary Pseudomonas aeruginosa infection in resistant and susceptible inbred mouse strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Infection and inflammation in cystic fibrosis: a short review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Cystic fibrosis pathogenesis and the role of biofilms in persistent infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

The role of inflammation in the pathophysiology of CF lung disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

Three new major somatic antigens of Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

based on heuristic

inferred from DOI database lookup

Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

based on heuristic

inferred from DOI database lookup

Negative control of flagellum synthesis in Pseudomonas aeruginosa is modulated by the alternative sigma factor AlgT (AlgU).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

based on heuristic

inferred from DOI database lookup

Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.080

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.08.080

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19744586

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50583511&oldid=1382125087"